ViiV bags EU okay for new two-drug HIV therapy

Dovato – a fixed-dose combination of ViiV’s blockbuster integrase inhibitor Tivicay (dolutegravir) and the nucleoside reverse transcriptase inhibitor lamivudine – is integral to the company’s attempt to muscle out

Shingrix lifts GSK in Q1, but two more vaccines are culled

The bulk of GSK’s HIV sales come from its dolutegravir-based combination products Tivicay and Triumeq, but greater competition in the market from arch-rival Gilead Sciences with new products ... That was particularly apparent for three-drug combo

Dovato approval key for Glaxo in HIV treatment

If the cost of prescribing Tivicay (dolutegravir) plus generic lamivudine is substantially lower than the cost of Dovato, it’s possible clinicians and payers could consider this approach.”.

Gilead awaits CEO and readouts to revive fortunes

It earned $551m in the fourth quarter and picked up both treatment-naïve patients and those switching from other drugs, including GSK’s rival drug Tivicay and its own established product

1 2 3 4 5 6 7 8 9 [ Next 5 results ]